Moderna, Inc. to Post Q3 2025 Earnings of $1.30 Per Share, William Blair Forecasts (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) – Stock analysts at William Blair increased their Q3 2025 EPS estimates for Moderna in a research report issued on Thursday, May 2nd. William Blair analyst M. Minter now anticipates that the company will post earnings of $1.30 per share for the quarter, up from their prior estimate of $1.25. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($7.47) per share. William Blair also issued estimates for Moderna’s Q4 2025 earnings at $1.36 EPS, FY2026 earnings at ($0.72) EPS and FY2027 earnings at $3.16 EPS.

Several other research firms also recently issued reports on MRNA. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Canaccord Genuity Group raised their price target on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research note on Friday. HSBC reiterated a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Oppenheimer lifted their target price on shares of Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a report on Friday. Finally, Royal Bank of Canada increased their price target on shares of Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus target price of $129.55.

Moderna Trading Down 2.3 %

Shares of Moderna stock opened at $122.13 on Monday. The company has a fifty day simple moving average of $105.61 and a 200-day simple moving average of $94.76. Moderna has a 12-month low of $62.55 and a 12-month high of $142.79. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. The stock has a market cap of $46.81 billion, a price-to-earnings ratio of -7.79 and a beta of 1.57.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business’s revenue for the quarter was down 91.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.19 EPS.

Institutional Trading of Moderna

Several large investors have recently bought and sold shares of the company. Allworth Financial LP increased its holdings in Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after acquiring an additional 101 shares in the last quarter. TIAA Trust National Association increased its stake in shares of Moderna by 2.3% during the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after purchasing an additional 102 shares in the last quarter. Principle Wealth Partners LLC raised its position in shares of Moderna by 4.3% during the 1st quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock worth $266,000 after purchasing an additional 102 shares during the last quarter. Sound Income Strategies LLC lifted its stake in Moderna by 17.8% in the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after buying an additional 115 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after buying an additional 116 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity

In related news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 647 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock valued at $14,822,576 in the last three months. 15.20% of the stock is currently owned by company insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.